Celsion (NASDAQ:CLSN) is set to issue its quarterly earnings data before the market opens on Tuesday, March 27th. Analysts expect the company to announce earnings of ($0.31) per share for the quarter.
Shares of Celsion (NASDAQ CLSN) opened at $2.47 on Monday. Celsion has a 52-week low of $1.24 and a 52-week high of $6.06. The company has a market capitalization of $43.80, a PE ratio of -0.42 and a beta of 1.80.
A number of analysts have commented on CLSN shares. ValuEngine raised Celsion from a “strong sell” rating to a “sell” rating in a research report on Wednesday, March 7th. Zacks Investment Research raised Celsion from a “sell” rating to a “hold” rating in a research report on Tuesday, December 19th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $11.90.
Celsion Corporation, an oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company's lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials for recurrent chest wall breast cancer.
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.